세계의 베타 지중해 빈혈 검사 시장 : 산업 규모, 점유율, 동향, 기회 및 예측 - 제품별, 기술별, 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Beta Thalassemia Testing Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product, By Technology, By Type, By End-User, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,511,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,957,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,575,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

베타 지중해 빈혈 검사 세계 시장 규모는 2024년 6억 495만 달러로 평가되었고, 예측 기간 동안 강력한 성장세를 보이며 2030년까지 연평균 9.28%의 성장률을 보일 것으로 예상됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	6억 495만 달러
시장 규모 : 2030년	10억 3,262만 달러
CAGR : 2025-2030년	9.28%
급성장 부문	키트
최대 시장	아시아태평양

이 시장은 전 세계적으로 베타 지중해 빈혈의 유병률 증가와 질병의 조기 발견 및 예방에 대한 관심이 높아짐에 따라 큰 성장세를 보이고 있습니다. 매년 수백만 명의 보균자와 수만 명의 신규 환자가 진단됨에 따라 전 세계 의료 시스템은 보균자 검진, 산전 진단 및 신생아 검사 프로그램을 우선순위에 두고 질병 전파를 완화하기 위해 노력하고 있습니다.

유전적 위험 평가에 대한 수요가 증가함에 따라 첨단 분자진단 도구의 채택이 가속화되고 있으며, 이러한 도구는 조기 진단의 정확성과 효율성을 높이고 장기적인 질병 관리를 개선하고 있습니다. 차세대 염기서열 분석(NGS), 중합효소연쇄반응(PCR) 기반 진단, 비침습적 산전검사(NIPT) 등의 기술 발전으로 특히 질병 부담이 높은 지역에서 검사의 접근성, 효율성, 비용 효율성이 향상되고 있습니다.

주요 시장 성장 촉진요인

베타 지중해 빈혈의 전 세계 유병률 상승

주요 시장 과제

자원이 부족한 지역의 의료 서비스 접근성 제한

주요 시장 동향

비침습적 산전검사(NIPT) 도입 확대

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 베타 지중해 빈혈 검사 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(키트, 소모품)
  • 기술별(산전 진단, 전혈구 계산, DNA 검사, 기타)
  • 유형별(중증형 지중해 빈혈, 중간형 지중해 빈혈)
  • 최종사용자별(병원, 전문 클리닉, 진단센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 베타 지중해 빈혈 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 베타 지중해 빈혈 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 베타 지중해 빈혈 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 베타 지중해 빈혈 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 베타 지중해 빈혈 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 베타 지중해 빈혈 검사 시장 : SWOT 분석

제14장 경쟁 구도

• MedGenome
• 3B BlackBio Biotech India Limited
• Bio-Rad Laboratories Inc.
• ViennaLab Diagnostics
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioMedomics Inc.
• Asper Biogene
• Tosoh Bioscience Inc.

제15장 전략적 제안

제16장 회사 소개 및 면책조항

LSH

영문 목차

영문목차

Global Beta Thalassemia Testing Market was valued at USD 604.95 million in 2024 and is projected to demonstrate strong growth throughout the forecast period, expanding at a compound annual growth rate (CAGR) of 9.28% through 2030.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 604.95 Million
Market Size 2030	USD 1032.62 Million
CAGR 2025-2030	9.28%
Fastest Growing Segment	Kits
Largest Market	Asia-Pacific

This market is experiencing significant momentum, fueled by the increasing global prevalence of beta thalassemia and the growing emphasis on early disease detection and prevention. With millions of carriers and tens of thousands of new cases diagnosed each year, healthcare systems worldwide are prioritizing carrier screening, prenatal diagnostics, and newborn testing programs to mitigate disease transmission.

The rising demand for genetic risk assessment is accelerating the adoption of advanced molecular diagnostic tools, which are enhancing the accuracy and efficiency of early diagnosis and improving long-term disease management. Technological advancements-such as next-generation sequencing (NGS), polymerase chain reaction (PCR)-based diagnostics, and non-invasive prenatal testing (NIPT)-are making testing more accessible, efficient, and cost-effective, particularly in regions with a high disease burden.

Key Market Drivers

Rising Global Prevalence of Beta Thalassemia

The growing global incidence of beta thalassemia is a primary catalyst for the market's expansion. Approximately 1.5% of the global population carries the B-thalassemia gene mutation, with higher prevalence observed in the Mediterranean, Middle East, South Asia, and Southeast Asia. The disorder affects an estimated 80 to 90 million individuals, driving significant demand for genetic testing, prenatal diagnostics, and carrier screening in these high-risk regions.

Each year, approximately 60,000 infants are born with B-thalassemia major, the majority in developing nations where access to diagnostic and therapeutic options is limited. Countries including India, Pakistan, Bangladesh, and Iran report particularly high prevalence rates, prompting governments and healthcare institutions to implement mandatory screening programs and improve diagnostic infrastructure.

Furthermore, the global migration of at-risk populations is expanding the geographic scope of beta thalassemia testing, increasing demand in regions such as Europe and North America. As the disease burden intensifies, health authorities are focusing on comprehensive testing strategies, thereby propelling the growth of specialized diagnostic markets.

Key Market Challenges

Limited Access to Healthcare in Low-Resource Settings

Despite rising demand, the beta thalassemia testing market faces constraints in developing and underserved regions, where healthcare infrastructure is often underdeveloped. A lack of medical facilities, trained personnel, and financial resources hampers the early diagnosis and management of beta thalassemia.

These limitations present significant barriers to market penetration, particularly in rural areas and low-income countries where the disease is most prevalent. Expanding diagnostic services in such environments requires considerable investment in infrastructure, education, and healthcare delivery systems. Market participants may face logistical and operational challenges when establishing testing facilities in these regions.

Key Market Trends

Increased Adoption of Non-Invasive Prenatal Testing (NIPT)

A transformative trend within the beta thalassemia testing market is the rapid adoption of non-invasive prenatal testing (NIPT). By analyzing fetal DNA from a maternal blood sample, NIPT offers a safe, accurate, and early method of detecting beta thalassemia without the risks associated with invasive procedures such as amniocentesis or chorionic villus sampling (CVS).

NIPT provides several advantages: high diagnostic precision, minimal risk to the fetus, and greater convenience for expectant parents. Growing awareness around early diagnosis and the availability of safer prenatal testing options is driving the widespread acceptance of NIPT.

Technological advancements in genomic sequencing and declining testing costs are making NIPT increasingly accessible to broader patient populations. As a result, diagnostic laboratories and healthcare providers are investing in NIPT infrastructure to meet rising demand and expand their prenatal screening services. This trend is expected to significantly boost market growth, particularly in regions with increasing emphasis on maternal-fetal health.

Key Market Players

• MedGenome
• 3B BlackBio Biotech India Limited
• Bio-Rad Laboratories Inc.
• ViennaLab Diagnostics
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioMedomics Inc.
• Asper Biogene
• Tosoh Bioscience Inc

Report Scope:

In this report, the Global Beta Thalassemia Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beta Thalassemia Testing Market, By Product:

• Kits
• Consumables

Beta Thalassemia Testing Market, By Technology:

• Prenatal Diagnosis
• Complete Blood Count
• DNA Testing
• Others

Beta Thalassemia Testing Market, By Type:

• Thalassemia Major
• Thalassemia Intermedia

Beta Thalassemia Testing Market, By End-User:

• Hospitals & Specialty Clinics
• Diagnostics Centers
• Others

Beta Thalassemia Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Beta Thalassemia Testing Market.

Available Customizations:

Global Beta Thalassemia Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Beta Thalassemia Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits, Consumables)
  • 5.2.2. By Technology (Prenatal Diagnosis, Complete Blood Count, DNA Testing, Others)
  • 5.2.3. By Type (Thalassemia Major, Thalassemia Intermedia)
  • 5.2.4. By End-User (Hospitals & Specialty Clinics, Diagnostics Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Beta Thalassemia Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Beta Thalassemia Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Beta Thalassemia Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Beta Thalassemia Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By End User

7. Europe Beta Thalassemia Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Beta Thalassemia Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Beta Thalassemia Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Beta Thalassemia Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By End User
  • 7.3.4. France Beta Thalassemia Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Beta Thalassemia Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Beta Thalassemia Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Beta Thalassemia Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Beta Thalassemia Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Beta Thalassemia Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Beta Thalassemia Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Beta Thalassemia Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By End User

9. South America Beta Thalassemia Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Beta Thalassemia Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Beta Thalassemia Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Beta Thalassemia Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Beta Thalassemia Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Beta Thalassemia Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Beta Thalassemia Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Beta Thalassemia Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Beta Thalassemia Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. MedGenome
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. 3B BlackBio Biotech India Limited
• 14.3. Bio-Rad Laboratories Inc.
• 14.4. ViennaLab Diagnostics
• 14.5. Thermo Fisher Scientific Inc.
• 14.6. PerkinElmer Inc.
• 14.7. BioMedomics Inc.
• 14.8. Asper Biogene
• 14.9. Tosoh Bioscience Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료